Greenlight Biosciences Holdings PBC (GRNA) Stock
GRNA is no longer traded. Greenlight Biosciences Holdings PBC was delisted from the Nasdaq in July 2023.
Prices on this page are historical; the last trade was July 21, 2023 at $0.30.
Greenlight Biosciences Holdings PBC stock price history
GRNA final trading statistics
- Final close
- $0.30
- Final trading day
- Jul 21, 2023
- Market cap at delisting
- $45.43M
- Shares outstanding
- 151.68M
- Final 52-week range
- $0.18 – $5.90
- Avg. volume (final 3 mo.)
- 690,030
- All-time high (split-adj.)
- $13.56 · Mar 2022
- All-time low (split-adj.)
- $0.18 · May 2023
- Return since IPO
- -96.6%
- Beta
- 1.44
- Book value / share
- $0.14
- Price / book
- 2.07
Greenlight Biosciences Holdings PBC annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $6.38M | -$167.1M | -$1.29 |
| FY2021 | $0.00 | -$114.7M | -$0.62 |
| FY2020 | $962.0K | -$54.3M | -$0.00 |
| FY2019 | $3.00M | -$29.0M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Greenlight Biosciences Holdings PBC
GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America. It provides cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company's plant and animal health pipeline includes Calantha for the Colorado potato beetle; Varroa mites, an RNA-based syrup that targets reproductive mites; Vegetable Caterpillar Complex, an dsRNA-based pesticide for the Diamond Back Moth; and Spider Mite Complex for the control of Tetranychus urticae. It also developing fungicides program for botrytis, fusarium, powdery mildew, downy mildew, Asian soybean rust, and rice blast; Gray Mold + for botrytis cinerea; Powdery mildew complex for the control of powdery mildew, caused by Erysiphe necator; and Mycotoxin control for Fusarium Head Blight, a cereal crop based diseases. In addition, the company also developing human health program comprising a phase I/II preclinical stage vaccine for COVID-19; and candidate selection vaccines for Shingles, and oncology. GreenLight Biosciences Holdings was formerly known as Environmental Impact Acquisition Corp. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Greenlight Biosciences Holdings PBC stock FAQ
What happened to Greenlight Biosciences Holdings PBC stock?
Greenlight Biosciences Holdings PBC stock was delisted from the Nasdaq. Its final close was $0.30 on July 21, 2023.
Is GRNA stock still trading?
No. GRNA was delisted from the Nasdaq in July 2023 and no longer trades on a U.S. exchange.
What was the last price of GRNA stock?
GRNA closed at $0.30 on its final trading day, July 21, 2023, for a market value of about $45.43M.
What were Greenlight Biosciences Holdings PBC's revenue and earnings in its last full fiscal year?
Greenlight Biosciences Holdings PBC reported revenue of $6.38M and net income of -$167.1M in fiscal 2022, its last full year as a public company.
When did Greenlight Biosciences Holdings PBC go public?
Greenlight Biosciences Holdings PBC stock began trading on February 3, 2022.